Disease Biomarkers in Multiple Sclerosis
@article{Harris2012DiseaseBI, title={Disease Biomarkers in Multiple Sclerosis}, author={V. K. Harris and S. A. Sadiq}, journal={Molecular Diagnosis & Therapy}, year={2012}, volume={13}, pages={225-244} }
Multiple sclerosis (MS) is an autoimmune disorder of the brain and spinal cord that predominantly affects white matter. MS has a variable clinical presentation and has no ‘diagnostic’ laboratory test; this often results in delays to definite diagnosis. In confronting the disease, early diagnosis and appropriate, timely therapeutic intervention are critical factors in ensuring favorable long-term outcomes.The availability of reliable biomarkers could radically alter our management of MS at… CONTINUE READING
27 Citations
Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: Prospective clinical and MRI follow-up study
- Medicine
- Journal of Neuroimmunology
- 2011
- 60
Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics.
- Biology, Medicine
- Journal of proteomics
- 2011
- 123
Gene expression signatures: biomarkers toward diagnosing multiple sclerosis
- Biology, Medicine
- Genes and Immunity
- 2012
- 26
- PDF
Glutamate and Nitric Oxide as biomarkers for disease activity in patients with multiple sclerosis.
- Medicine
- Multiple sclerosis and related disorders
- 2019
- 3
Utility of Myelin Basic Protein as an Early Prognostic Biomarker in Multiple Sclerosis
- Medicine
- 2016
- PDF
Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations.
- Medicine
- The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
- 2020
- 3
- PDF
References
SHOWING 1-10 OF 219 REFERENCES
Identification of molecular biomarkers for multiple sclerosis.
- Medicine
- The Journal of molecular diagnostics : JMD
- 2007
- 27
- PDF
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.
- Medicine
- The New England journal of medicine
- 2003
- 584
- PDF
Lack of association between antimyelin antibodies and progression to multiple sclerosis.
- Medicine
- The New England journal of medicine
- 2007
- 146
Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis
- Medicine
- Multiple sclerosis
- 2006
- 37
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis
- Biology, Medicine
- Proceedings of the National Academy of Sciences
- 2008
- 214
- PDF
Epidemiology and natural history of multiple sclerosis: new insights
- Medicine
- Current opinion in neurology
- 2006
- 170
- PDF
Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis
- Medicine
- Multiple sclerosis
- 2005
- 54
Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS
- Medicine
- Multiple sclerosis
- 2007
- 58
Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis.
- Medicine
- Archives of neurology
- 2008
- 42
- PDF